Zealand Pharma Plummets as Gastrointestinal Side Effects Cloud Survodutide’s Commercial Path
Shares of Zealand Pharma crashed following data showing a 19% dropout rate due to GI issues in its experimental weight loss drug survodutide.
Tag: Obesity Treatment